Stefanie Schmidt1, Albert Francés2, José Antonio Lorente Garin2, Nuria Juanpere3, José Lloreta Trull4, Xavier Bonfill5, María José Martinez-Zapata6, Maria Morales Suarez-Varela7, Javier de la Cruz8, José Ignacio Emparanza9, María-José Sánchez10, Javier Zamora11, José Ignacio Pijoan12, Jordi Alonso1, Montse Ferrer13. 1. Health Services Research Group, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain. 2. Department of Urology, Hospital del Mar, Barcelona, Spain. 3. Department of Pathology, Hospital del Mar, Barcelona, Spain. 4. Department of Experimental and Health Sciences, Universitat Pompeu Fabra (UPF), Barcelona, Spain; Department of Pathology, Hospital del Mar, Barcelona, Spain. 5. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain; Department of Pediatric, Obstetrics and Gynecology and Preventive Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 6. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. 7. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Unit of Public Health and Environmental Care, Department of Preventive Medicine, University of Valencia, Valencia, Spain; Center for Public Health Research (CSISP), Valencia, Spain. 8. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Clinical Research Unit, Hospital 12 de Octubre, Madrid, Spain. 9. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Clinical Epidemiology Unit, Hospital Universitario Donostia, BioDonostia, San Sebastian, Spain. 10. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. 11. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Clinical Biostatistics Unit, Hospital Ramón y Cajal (IRYCIS), Madrid, Spain. 12. CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Clinical Epidemiology Unit, Hospital Universitario Cruces, BioCruces, Barakaldo, Spain. 13. Health Services Research Group, IMIM-Hospital del Mar Medical Research Institute, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Spain; Department of Pediatric, Obstetrics and Gynecology and Preventive Medicine, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Electronic address: mferrer@imim.es.
Abstract
OBJECTIVE: Few studies describe the effect of non-muscle-invasive bladder cancer (NMIBC) on health-related quality of life (HRQL), although patients are mostly diagnosed at this stage of the disease. Taking into account this current evidence gap and the high incidence rates in Spain, we aimed to describe the evolution over time of HRQL in Spanish patients with NMIBC and to examine the clinical and treatment-related factors associated with HRQL change during the first year of management. METHODS AND MATERIALS: Observational multicenter prospective inception cohort study conducted in urology departments of 7 Spanish hospitals. A consecutive sample of 244 patients with anatomopathologically confirmed NMIBC, recruited from October 2010 to September 2011, was followed during the diagnostic process, and 6 and 12 months later. HRQL was assessed by generic and disease-specific instruments: the Short Form-36 (covering physical and mental health) and the Bladder Cancer Index, measuring urinary, bowel, and sexual domains (summary scores: 0-100). Bivariate analysis was performed and generalized estimating equation models were constructed to assess HRQL score change. RESULTS: Almost 52% of the patients were diagnosed at stage I, and 84% were men. The number of patients treated only with transurethral resection (TUR) was 144, and 82 also received intravesical therapy with bacillus Calmette-Guérin (BCG) or mitomycin C. Mental health was significantly worse than Short Form-36 reference norms at diagnosis (mean of 49.7 vs. 53.3, 95% CI: 52.5-54.2). Urinary domain improved significantly from diagnosis (85.2, 95% CI: 82.9-87.4) to 12-month evaluation (90.2, 95% CI: 87.7-92.8), whereas sexual domain showed deterioration from 56.4 (95% CI: 52.8-59.9) to 53.7 (95% CI: 50.0-57.4). Adjusted HRQL score changes from baseline to 12-month follow-up estimated with generalized estimating equation models showed improvement on the following parameters: urinary domain after TUR with or without intravesical therapy (+3.9, 95% CI: 0.1-7.7), bowel domain among patients treated with TUR and BCG (+7.0, 95% CI: 2.4-11.5), and sexual domain among those treated with TUR and mitomycin C (+13.1, 95% CI: 5.9-20.2). CONCLUSIONS: For the first time, a distinctive HRQL pattern of bladder cancer treatment benefits emerges for TUR alone, and in combination with BCG or mitomycin C, which deserves further research. Treatment differences cannot be interpreted in terms of efficacy but can be useful to generate hypotheses to test in future studies.
OBJECTIVE: Few studies describe the effect of non-muscle-invasive bladder cancer (NMIBC) on health-related quality of life (HRQL), although patients are mostly diagnosed at this stage of the disease. Taking into account this current evidence gap and the high incidence rates in Spain, we aimed to describe the evolution over time of HRQL in Spanish patients with NMIBC and to examine the clinical and treatment-related factors associated with HRQL change during the first year of management. METHODS AND MATERIALS: Observational multicenter prospective inception cohort study conducted in urology departments of 7 Spanish hospitals. A consecutive sample of 244 patients with anatomopathologically confirmed NMIBC, recruited from October 2010 to September 2011, was followed during the diagnostic process, and 6 and 12 months later. HRQL was assessed by generic and disease-specific instruments: the Short Form-36 (covering physical and mental health) and the Bladder Cancer Index, measuring urinary, bowel, and sexual domains (summary scores: 0-100). Bivariate analysis was performed and generalized estimating equation models were constructed to assess HRQL score change. RESULTS: Almost 52% of the patients were diagnosed at stage I, and 84% were men. The number of patients treated only with transurethral resection (TUR) was 144, and 82 also received intravesical therapy with bacillus Calmette-Guérin (BCG) or mitomycin C. Mental health was significantly worse than Short Form-36 reference norms at diagnosis (mean of 49.7 vs. 53.3, 95% CI: 52.5-54.2). Urinary domain improved significantly from diagnosis (85.2, 95% CI: 82.9-87.4) to 12-month evaluation (90.2, 95% CI: 87.7-92.8), whereas sexual domain showed deterioration from 56.4 (95% CI: 52.8-59.9) to 53.7 (95% CI: 50.0-57.4). Adjusted HRQL score changes from baseline to 12-month follow-up estimated with generalized estimating equation models showed improvement on the following parameters: urinary domain after TUR with or without intravesical therapy (+3.9, 95% CI: 0.1-7.7), bowel domain among patients treated with TUR and BCG (+7.0, 95% CI: 2.4-11.5), and sexual domain among those treated with TUR and mitomycin C (+13.1, 95% CI: 5.9-20.2). CONCLUSIONS: For the first time, a distinctive HRQL pattern of bladder cancer treatment benefits emerges for TUR alone, and in combination with BCG or mitomycin C, which deserves further research. Treatment differences cannot be interpreted in terms of efficacy but can be useful to generate hypotheses to test in future studies.
Authors: Ahrang Jung; Matthew E Nielsen; Jamie L Crandell; Mary H Palmer; Sophia K Smith; Ashley Leak Bryant; Deborah K Mayer Journal: BJU Int Date: 2019-09-25 Impact factor: 5.588
Authors: Samantha J Mason; Amy Downing; Penny Wright; Sarah E Bottomley; Andrew Winterbottom; Adam W Glaser; James W F Catto Journal: BMJ Open Date: 2019-06-17 Impact factor: 2.692
Authors: Lauren J Lee; Christina S Kwon; Anna Forsythe; Carla M Mamolo; Elizabeth T Masters; Ira A Jacobs Journal: Clinicoecon Outcomes Res Date: 2020-11-23
Authors: N E Mohamed; F Gilbert; C T Lee; J Sfakianos; C Knauer; R Mehrazin; H Badr; D Wittmann; T Downs; D Berry; B Given; P Wiklund; G Steineck Journal: Bladder Cancer Date: 2016-04-27
Authors: Edward Cox; Pedro Saramago; John Kelly; Nuria Porta; Emma Hall; Wei Shen Tan; Mark Sculpher; Marta Soares Journal: Clin Genitourin Cancer Date: 2019-12-14 Impact factor: 2.872
Authors: Wei Shen Tan; Chin Hai Teo; Delcos Chan; Kar Mun Ang; Malgorzata Heinrich; Andrew Feber; Rachael Sarpong; Norman Williams; Chris Brew-Graves; Chirk Jenn Ng; John Kelly Journal: BJU Int Date: 2020-02-12 Impact factor: 5.588